BioCentury
ARTICLE | Clinical News

Lyxumia lixisenatide: Additional Phase III data

June 25, 2012 7:00 AM UTC

Additional data from the double-blind, international Phase III GetGoal-L trial in 495 Type II diabetics inadequately controlled with basal insulin showed that once-daily 20 µg Lyxumia as an add-on to basal insulin with or without metformin significantly reduced HbA1c from baseline to week 24, the primary endpoint, by 0.74% vs. 0.38% for placebo (p=0.0002). Lyxumia also led to significant mean reductions in body weight (1.8 vs. 0.52 kg, p<0.0001) and 2-hour post-prandial plasma glucose after a standardized breakfast (5.52 vs. 1.72 mmol/L, p<0.0001) vs. placebo. Data were presented at the American Diabetes Association meeting in Philadelphia. Sanofi previously reported top-line data showing that Lyxumia met the primary endpoint of reducing HbA1c from baseline to week 24 vs. placebo (see BioCentury, June 6, 2011). ...